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Summary We have investigated the secretion of interferon a (IFN-a). IFN-y, interleukin-1 a (IL-1a), IL-15, IL-2 and tumour necrosis factor a
(TNF-a) in whole blood cell cultures (WBCCs) of colorectal cancer patients upon mitogen stimulation. Whereas the values for IL-1i and TNF-
a remained virtually unchanged in comparison with healthy control subjects, WBCCs of colorectal cancer patients secreted significantty lower
amounts of IFN-a (P < 0.005), IFN-y(P < 0.0001), IL-1 a (P < 0.0001) and IL-2 (P < 0.05). This reduction correlated with the progression of the
disease. The total leucocyte and monocyte population were almost identical in both groups. In contrast. a dramatic depletion of lymphocytes
was observed in colorectal cancer patients, which affected both lymphocyte counts (P < 0.0005) and their distribution (P < 0.0001). Our
results suggest a selective suppression of cytokines in colorectal cancer patients that is related to tumour burden. Several mechanisms might
account for this phenomenon. one of which might be lymphocyte depletion.
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Patients sufferinn from solid tumours frequently show a depressed
function of their immunocompetent cells. Such immunodeficien-
cies haxe been reported in patients with different types of carci-
noma. including colorectal cancer (Wanebo et al. 1980: Bodmer et
al. 1989: Yoshino et al. 1992: O'Sullixan et al. 1996).
Soluble cvtokines are important regulatory molecules of
numerous immune responses. The measurement of cvtokine
production might. therefore. be a helpful parameter to assess the
immunological competence of tumour patients. Sexeral groups.
including our ow-n. have reported selective changes in the cvtokine
profile secreted by lymphocytes and monocytes of carcinoma
patients (Rev et al. 1983: Elsasser-Beile et al. 1993a.b: Fischer et
al. 1995: De Groote et al. 1996). Such a reduction might at least in
part occur as a consequence of soluble immunosuppressix e factors
that are released bv tumour cells (Ebert et al. 1990: Fischer et al.
1994). We recentl1 show-ed that a decrease in IL-2 production in
whole blood cell cultures (WBCCs) is correlated with a poor
survixal rate in small-cell lung cancer patients (Fischer et al.
1997). underlining the importance of an exactlv balanced equilib-
rium of cvtokine concentrations.
In the present report wxe inx estigated cx tokine secretion bv
peripheral leucocytes in patients w ith colorectal cancer. We
provide exidence that the lexels of IFN-a. IFN-y. IL- 1 a and IL-2
are selectixelv reduced in colorectal cancer patients compared
w ith healthy control subjects. In addition. w e hax e obserxed
sexere alterations in the lymphocyte compartment of the carci-
noma patients.
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MATERIALS AND METHODS
Patients
Blood samples were tak-en from -4 healthy x olunteers (mean age 52
years. range 29-62) and from 28 patients (17 male. 11 female) wxith
histologicallv confirmed colorectal carcinoma (mean age 67 -ears.
range 40-82). In 13 patients early stages w ere diacnosed (Dukes' A
and B). whereas 15 showxed progressed stages of colorectal carci-
noma (Dukes' C and D). None of the patients had receixed chemo-
or radiotherapy before the time wxhen blood w as taken.
Reagents
Phvtohaemagglutinin-M (PHA xxas purchased from 'Wellcome
(Reinach. Sw itzerland ). The Newxcastle disease X irus (NDV)
preparation xas kindly proxvided by Dr R Zawatzky (Gernan
Cancer Research Center. Heidelberg. Germany).
Blood samples
Heparinized blood (20 ml) w as tak-en between 08.00 and 11.00 h
from healthyx volunteers or cancer patients and used wxithin 3 h for
further investigations. In parallel. total and differential leucocyte
counts x ere determined automatically from the same xenous
puncture.
Whole blood cell culture and stimulation of cytokine
secretion
Heparinized blood xxas diluted 1:5 in RPMI-1640 (Gibco. Grand
Island. NY. USA) supplemented wxith Hepes (10 msm final
concentration). L-glutamine (2 m\t final concentration). penicillin
(100 U ml-'). streptomycmn (100 !g ml- ) and 10%1 fetal calf serum
(FCS) (Seromed. Berlin. Germany). Aliquots of 1 ml were distrib-
uted into 24-wxell plates (Costar. Cambridoe. MA. USA).
1018
Cytokine secretion in colon cancer patients 1019
Stimulation of cytokine secretion was performed as presiously
described Elsasser-Beile et al. 1991: Fischer et al. 1995) with
slinht modifications. Cells were cultured at 37'C and 517% carbon
dioxide in a fully humidified atmosphere in the presence of NDV
(1:100 final dilution) or PHA ( 10 jgc ml-' final concentration) to
stimulate the secretion of IFN-ax or the other cytokines respec-
tivelv. Cell supernatants (SNs) were harvested after 24 h (TNF-ac
IL-5)*. 48 h (IL-2. IFN-(x) or 72 h (IL-laILFN-y). centrifuged at
600 g to remove cellular debris and stored in aliquots at - 20°C
until further use.
Determination of cytokine concentrations
SNs were tested for the presence of IL-I a. IL-I B. IL-2. IFN-a.
IFN-y and TNF-a using an enzvme-linked immunosorbent assav
(ELISA) as previously described (Elsasser-Beile et al. 1991).
Brieflv. recombinant cvtokines and cell SNs were incubated with a
murine monoclonal antibody that had previously been coupled to a
microtitre plate. Thereafter. a second anti-cvtokine monoclonal
antibody conjugated with peroxidase was added. After an incuba-
tion time of 16-24 h the peroxidase activity was determined by a
redox indicator. The intensitv of the colour measured with a multi-
channel photometer is directly proportional to the cytokine
concentration. Linearitv of standard curves was obtained within
the followinc ranges: -l00pg ml' (IL-la). 25-1000pcg ml-'
(IL-1I3). 20-1000 pg ml (IL-2). 0.5-10 U ml-' (IFN-a). 10-
1000 p ml- IFN-y) and 10-1000 pg ml-' (TNF-a). For each
determination. SNs from duplicate wells were prepared.
Statistical analysis
The sianificance of differences between the results in the patient
group and control subjects was calculated by usinc the Wilcoxon
rank-sum test. the Kruskal-Wallis test and the Mann-Whitney
rank-sum test.
RESULTS
Cytokine secretion in whole blood cell cultures of
normal individuals
We first established the normal range of cytokine production in
WBCCs in a group of -4 healthy adults according to previously
established protocols (Fischer et al. 1995). The secretion profiles
for IFN-a. IFN-y. IL-la. IL-15. IL-2 and TNF-a are shown in
Table 1. Others have pointed out a potential decrease in cytokine
levels with an increase in age (Elsasser-Beile et al. 1993a).
However. when we insestigated the cytokine secretion in this
group we did not find any age-dependent variations (Fischer et al.
1995). This excludes that differences in the capacity to secrete
cytokines simply reflect differences of age.
Cytokine levels in patients with colorectal carcinoma
are selectively reduced
Having established the concentration in the control group. we
compared the capacity of WBCCs from colorectal cancer patients
to secrete these cytokines. The concentrations of TNF-a and IL- 1
in the cancer patient group did not differ significantly from control
subjects. Interestingly. patients with early stages of colorectal
carcinoma had significantly enhanced TNF-a levels (Table 1). In
A
20 0000-
160 000-
120 000 -
80 ooo -
40 Woo -
0.f
z
LU
0
B
50
0
P< 0.05
0
*c DukeaB
Control Dukes'AB
P < 0.0001
0
Dukes' CD
400 -
P = 0.07
300 - 0
.-
S-
200-
100 -
P < 00001
0
.ontrc~ DukesAB
Control Dukes'AB
D
Dukes CD
Figure 1 Impaired secretion of IFN-y (A) and IL-la (B) in whole blood cell
cultures of colorectal carcinoma patients after mitogen stimulation. Data are
presented as whisker plots showing median value (-). mean value (....).
upper and lower quartile and range. P-values designate differences between
patents and control group
contrast. [FN-a. IFN-y. IL- la and IL-2 were secreted at signifi-
cantly' lower concentrations. The reduction in the colorectal carci-
noma group was between 31% (IL-2) and 63%e (IFN-y). We
analysed a potential correlation betmeen progression of the disease
from earlv (Dukes' A and B) towards ads anced stages (Dukes' C
and D) and reduction in cytokine secretion. For all four cytokines
that were secreted at lower concentrations the progression of the
disease went along with a reduction in the capacity of WBCCs to
produce the cytokine. The progression from early (Dukes' A and
B) to advanced stages (Dukes' C and D) coincided with a signifi-
cant reduction in IL- 10 secretion (P < 0.05). whereas the decrease
in IFN-y reached borderline significance (P = 0.056).
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Table 1 Cytokine secretion in whole-blood cell cultures from colorectal cancer patents
Cytoldnea Control PatIents Dukes' AB Dukes' CD
(n= 44) (n = 28) (n = 13) (n = 15)
IFN-a
Mean (U mVt) 111.28 55.48 71.11 41.93
s.d. 110.80 59.32 57.24 57.73
950 Cl 78.54-144.02 33.50-77.45 39.99-102.23 12.71-71.15
P-value 0.0022 0.212 0.0005
FN-y
Mean (pg mVl) 71240 28396 35918 18144
s.d. 57190 26651 27829 22538
95o0 Cl 54341-88138 16525-36268 20790-51046 6738-29550
P-value < 0.0001 0.0242 < 0.0001
IL-1 a
Mean (pg mt ) 145.18 83.83 124.23 48.83
s.d. 84.01 110.21 144.63 43.63
950O Cl 120.35-170.00 43.01-124.66 45.6G-202.85 26.74-70.92
P-value 0.0001 0.069 <0.0001
IL-1 P
Mean (pg ml-) 1460 1616 1926 1346
s.d. 1135 1851 1228 2221
950 Cl 1125-1796 930-2301 1259-2594 222-2470
P-value 0.640 0.202 0.0612
IL-2
Mean (pg mt-) 3085 2125 2757 1578
s.d. 2616 2190 2919 959
9500 Cl 2312-3858 1314-2937 1170-4344 1092-2064
P-value 0.0168 0.246 0.0110
TNF-a
Mean (pg ml-) 995 1818 2398 1315
s.d. 711 1998 2059 1798
950° Cl 784-1205 1078-2553 1278-3517 405-2225
P-value 0.095 0.0127 0.814
s.d.. standard deviation, Cl, confidence interval; P-values: compared with control subjects. aCytokines were dcetermined
after stimulatin of WBCC with PHA or NDV as indicated in Materials and methods.
Interestinglv. in earlv stages with limited disease only, IFN-y
values were significantly reduced compared with the control
group. With progression to advanced stages. the concentrations of
all four cytokines were significantly reduced in comparison with
normal healthy persons. Only 26%7 (WFN-y) to 51%7 (WL-2) of the
normal amount of cytokine was produced (Table 1). Of all
cytokines tested. LFN-y correlated best with the progression of
colorectal cancer (Figure IA). A similar tendency. although less
pronounced. was seen for IL-la secretion (Figure 1B). The in'ves-
tigation of further parameters within the carcinoma group such as
location of the primary tumour site or sex did not show anv signif-
icant differences. In addition. the presence or absence of metas-
tases was not reflected in a significantly different cytokine level.
Lymphocytes are severely depleted in colorectal cancer
patients
In order to determine w-hether the observed alterations mav be due
to a depletion of lvmphocvtes and/or monocytes we determined
total and differential leucocyte counts. The total leucocvte counts
did not vary significantly between the control population and the
patient group. regardless of the stage of disease (Table 2).
Likewise. the monocyte population did not show major alterations.
although both the number (Table 2) and the percentage (Table 3) in
patients with advanced disease were slightly enhanced. In contrast.
the lymphocyte population in colorectal cancer patients appears to
have undergone dramatic changes. Overall. approximately 301%
less lymphocytes was present in cancer patients. This reduction
was already evident in earlv stages and became highly significant
in advanced disease. where only about 55% of lymphocytes was
counted (Table 2). Lymphocyte numbers between early and
advanced stages of colorectal cancer differed significantly
(P < 0.01). With respect to the distribution. the scenery was even
more pronounced. Already patients with early stages of colorectal
cancer (Dukes' A and B) had only 24% lymphocytes as compared
with about 30% of healthy control subjects. In patients with
advanced stages (Dukes' C and D) only 18%7 of the leucocvtes
were lymphocytes. Thus. whereas monocytes were apparently
unchanred. the lymphocytic department had undergone dramatic
changes in the colorectal cancer patient population.
DISCUSSION
In the present study we demonstrate that WBCCs from colorectal
cancer patients have an impaired capacity to secrete cytokines
upon mitogen stimulation. The selected mitogens act on different
immune cells. NDV induces IFN-a production on monocytes.
whereas PHA mainly acts on T cells. However. PHA can also stim-
ulate cytokine secretion in monocytes. either directly (Neustock et
al. 1993) or indirectly through PHA-activated T cells by cell-cell
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Table 2 Leucocyte counts in colorectal cancer patients
Control Patent Dukes' AB Dukes' CD
(n = 44) (n = 28) (n = 13) (n = 15)
Leucocytes
Meana 7.51 8.01 8.76 7.36
s.d. 2.00 2.32 2.83 1.49
95% Cl 6.92-8.11 7.14-8.87 7.22-10.30 6.60-8.11
P-value 0.396 0.171 0.979
Monocytes
Meana 0.46 0.54 0.47 0.59
s.d. 0.38 0.18 0.15 0.19
950o CI 0.34-0.57 0.47-0.61 0.38-0.55 0.50-0.69
P-value 0.069 0.687 0.019
Lymphocytes
Meana 2.25 1.59 1.95 1.28
s.d. 0.77 0.68 0.54 0.62
950o Cl 2.02-2.48 1.34-1.84 1.66-2.25 0.96-1.59
P-value 0.0005 0.158 0.0001
aCell number x 103 mm---' s.d. standard deviabion: Cl. confidence interval, P-values: compared with controls subjects.
Table 3 Leucocyte distribution in colorectal cancer patients
Cytoldne Control Pabent Dukes' AB Dukes' CD
(n = 44) (n = 28) (n = 13) (n = 15)
Monocyte distribution
Mean (co) 6.81 7.12 6.09 8.00
s.d. 7.80 2.57 2.23 2.51
950° Cl 4.51-9.12 6.17-8.07 4.87-7.30 6.72-9.27
P-value 0.153 0.890 0.047
Lymphocyte distribution
Mean (%) 30.27 20.75 24.27 17.76
s.d. 9.66 8.17 5.10 9.05
950 Cl 27.41-33.12 17.75-23.77 21.50-27.04 13.18-22.35
P-value < 0.0001 0.0072 0.0002
s.d. standard deviation: Cl. confidence interval: P-values: compared with controls subjects.
contact (Li et al. 1995). The selected panel of cytokines covers both
T cells and monocytes. i.e. the vast majority of cytokine-producinc
cells in peripheral blood. Alterations might. therefore. be a good
indication of an impaired immunocompetence.
The levels of IFN-ca IFN-y. IL-la and IL-2 were significantly
reduced in WBCCs of patients as compared with the control popu-
lation. In a previous report we investigated cytokine secretion in
lung cancer patients. In WBCCs of small-cell lunc cancer and non-
small-cell lung cancer patients secretion of IL- 1 a was not reduced
(Fischer et al. 1995). In contrast. WBCCs of patients suffering,
from bladder carcinoma contained significantly less TNF-a than
WBCCs of control subjects (Elsasser-Beile et al. 1993b). Thus. the
cytokine reduction does not appear at random but rather as a
consequence of the respective tumour. Our results also show that
cytokine-secreting peripheral immune cells from colorectal cancer
patients are not commonly suppressed as they display a virtually
unchanged capacity to secrete IL-1 and TNF-a. indicating that
the suppression is selective.
The measured cytokine concentration correlated with progres-
sion of the tumour. Patients with advanced colon cancer (Dukes' C
and D) had significantly reduced levels of IFN-a. WN-y. IL-la
and IL-2 compared with the control group. Dungn early stages the
decrease was rather marginal (between 101% and 36%7) except for
IFN-y (> 50%c reduction). The latter cytokine showed the most
pronounced suppression of all cytokines tested (approximately
75%7 reduction at advanced stages). similar to results obtained in
other studies with different types of tumors (Elsasser-Beile et al.
1993a.b: Fischer et al. 1995).
Rather unexpected was our finding of a dramatic lvmphocyte
depletion in colorectal cancer patients. which is in contrast to
a previous publication (Elsasser-Beile et al. 1992). There is
evidence. however. that lvmphocytopenia is significantly osver-
represented in populations known to be at high risk for colorectal
cancer (Bang and Laing. 1986). and reduced lymphocyte counts
were associated with the appearance of colorectal polyps (Robins
et al. 1991). There are reports that tumour cells secrete soluble
factors that induce apoptosis in the T-cell population (Billings et
al. 1997). Malignant melanoma cells produce the Fas ligand
(FasL) and can directly induce apoptosis in Fas-sensitive target
cells. Tumour growth of such melanoma cells was retarded in
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Fas-deficient I pr mice where immune cells are resistant to FasL-
induced apoptosis (Hahne et al. 1996). Normal colonic cells do not
express FasL. In contrast. FasL mRNA and protein were detected
in some primary and in all of the investigated metastatic colorectal
tumours (Shiraki et al. 1997). Experiments using established
colorectal carcinoma cell lines confirmed that FasL is biolo2icallv
active (Shiraki et al. 1997: O' Connell et al. 1996). The expression
of bioactiv-e FasL preferentially in metastatic colorectal tumour
cells could explain our finding that advanced stages that have
already developed metastases show a more pronounced lympho-
c-te depletion. Thus. one might speculate that colon carcinoma-
derived soluble factors contribute directly to the observed
lymphocyte reduction.
IFN-y and IL-2 are mainly produced by T lvmphocvtes.
Consequently. the depletion of the lymphocyte compartment
should. therefore. lead to a reduced concentration of these
cvtokines in WBCC supernatants upon mitogen stimulation. In
contrast. the number of monocvtes - the main source of IL- 1 a -
w-as virtually unchanged in colorectal carcinoma patients.
Nevertheless. IL- 1 a levels correlated nenativelv with malignant
progression. suggesting that the garowing, tumour was the causatiVe
reason for this behaviour. One attractive hypothesis to explain this
phenomenon could be the secretion of soluble immunosuppressive
factors bv tumour cells. therebv creating a local milieu of
decreased immune surveillance. Such factors have been described
in several malianancies includinc colorectal carcinomas (Ebert et
al. 1990: Ikeda et al. 1991: Bodmer et al. 1989: Hersey et al. 1983:
Yoshino et al. 1993: O'Sullivan et al. 1996). We have recently
identified transforming arowth factor P1 (TGF-01l) as an immuno-
suppressive factor that is released by small-cell lung cancer cells
(Fischer et al. 1994). Human colorectal carcinoma cells also
frequently produce TGF-1I (Lahm and Odartchenko. 1993).
which is an effective and selective suppressor of cvtokine secre-
tion by peripheral lymphocstes (Fischer et al. 1995). Furthermore.
secretion of IL- 10. another potent inhibitor of cytokine secretion.
was found to be highest and most common in cell lines derived
from colorectal carcinomas (GastI et al. 1993). Animals treated
with IL-10 showed a reduced expression of several cvtokines.
including IFN-y. IL-1 and IL-2 (Herfarth et al. 1996). Thus.
different soluble immunosuppressive factors including TGF-p1.
IL-10 and FasL. which are released by neoplastic cells. mi'nht
differentially alter the cvtokine secretion profile of immune cells
and in turn impair their physiological functions.
In summars-. we have shown selective suppression of cvtokine
secretion in colorectal carcinoma patients that coincided with
tumour burden. The altered cvtokine profile might be a conse-
quence of soluble tumour-derived immunemodulatorv and cvto-
toxic factors that may also severely impair the lymphocyte
compartment. The identification of such mediators could provide
new insiahts into the relationship between colorectal tumour cells
and the immune system and possibly offer alternati-e therapeu-
tical approaches.
ABBREVIATIONS
ELISA. enzyme-linked immunosorbent assay: FasL. Fas licand:
IFN. interferon: IL. interleukin: NDV. Newcastle disease virus:
PHA. phytohaemagglutinin-M: SN. supernatant: TGF. trans-
forming growth factor: TNT. tumour necrosis factor: WNBCC.
whole blood cell culture.
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